Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalotuzumab + Gemcitabine/Carboplatin in Advanced Squamous NSCLC
NCT00951444Phase 2Withdrawn
- Sponsor
- Cancer and Leukemia Group B
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of dalotuzumab in squamous cell carcinoma of the lung (SCCL), sponsored by Cancer and Leukemia Group B. Status: withdrawn.
02
Drugs
dalotuzumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT00951444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951444.